Adynxx (ADYX) 10-Q 5 Nov 15 2015 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 02, 2015
Document Information [Line Items]
Entity Registrant Name	Alliqua BioMedical, Inc.
Entity Central Index Key	1,054,274
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	ALQA
Entity Common Stock, Shares Outstanding		27,668,913
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,015

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Current Assets:
Cash and cash equivalents	$ 30,731,728	$ 16,770,879
Accounts receivable, net	2,389,411	968,616
Inventory, net	3,478,955	1,411,748
Prepaid expenses and other current assets	934,824	477,824
Total current assets	37,534,918	19,629,067
Improvements and equipment, net	1,784,563	1,434,027
Intangible assets, net	34,783,056	4,387,293
Goodwill	20,798,933	4,100,295
Other assets	172,868	173,042
Total assets	95,074,338	29,723,724
Current Liabilities:
Accounts payable	2,843,448	1,757,742
Accrued expenses and other current liabilities	3,121,172	2,067,859
Contingent consideration, current	5,751,688	0
Warrant liability	1,567,364	304,223
Total current liabilities	13,283,672	4,129,824
Long-term debt, net	11,887,283	0
Contingent consideration, long-term	13,707,642	2,931,598
Deferred tax liability	1,513,665	67,000
Other long-term liabilities	77,818	84,071
Total liabilities	$ 40,470,080	$ 7,212,493
Commitments and Contingencies
Stockholders' Equity
Preferred Stock, par value $0.001 per share, 1,000,000 shares authorized, no shares issued and outstanding	$ 0	$ 0
Common Stock, par value $0.001 per share, 45,714,286 shares authorized; 27,668,913 and 16,202,689 shares issued and outstanding as of September 30, 2015 and December 31, 2014, respectively	27,669	16,203
Additional paid-in capital	146,403,295	92,537,742
Accumulated deficit	(91,826,706)	(70,042,714)
Total stockholders' equity	54,604,258	22,511,231
Total liabilities and stockholders' equity	$ 95,074,338	$ 29,723,724

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] - $ / shares	Sep. 30, 2015	Dec. 31, 2014
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	45,714,286	45,714,286
Common stock, shares issued	27,668,913	16,202,689
Common stock, shares outstanding	27,668,913	16,202,689

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenue, net of returns, allowances and discounts	$ 5,013,835	$ 1,493,840	$ 10,263,789	$ 3,121,863
Cost of revenues	1,661,045	915,811	4,241,711	2,384,225
Gross profit	3,352,790	578,029	6,022,078	737,638
Operating expenses
Selling, general and administrative, (inclusive of stock-based compensation of $2,166,108 and $6,307,252 for the three and nine month periods ended September 30, 2015 and $1,779,134 and $8,875,080 for the three and nine month periods ended September 30, 2014 - see Note 9)	10,375,987	5,480,380	25,307,906	20,083,015
Research and product development	192,243	0	492,677	0
Acquisition-related	15,000	61,330	2,875,586	546,970
Change in fair value of contingent consideration liability	585,141	194,034	957,732	194,034
Total operating expenses	11,168,371	5,735,744	29,633,901	20,824,019
Loss from operations	(7,815,581)	(5,157,715)	(23,611,823)	(20,086,381)
Other (expense) income
Interest expense	(667,010)	0	(900,049)	(384)
Interest income	12,514	8,779	31,704	22,755
Change in value of warrant liability	1,466,208	48,993	1,388,071	(19,324)
Total other income	811,712	57,772	519,726	3,047
Net loss before income tax	(7,003,869)	(5,099,943)	(23,092,097)	(20,083,334)
Income tax (expense) benefit	(128,795)	(3,500)	1,308,105	(10,500)
Net loss	$ (7,132,664)	$ (5,103,443)	$ (21,783,992)	$ (20,093,834)
Basic and diluted net loss per common share (in dollars per share)	$ (0.26)	$ (0.33)	$ (1)	$ (1.41)
Weighted average shares used in computing basic and diluted net loss per common share (in shares)	26,930,880	15,666,697	21,742,504	14,269,239

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Parenthetical] - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Allocated Share-based Compensation Expense	$ 2,166,108	$ 1,779,134	$ 6,307,252	$ 8,875,080

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - 9 months ended Sep. 30, 2015 - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2014	$ 22,511,231	$ 16,203	$ 92,537,742	$ (70,042,714)
Balance (in shares) at Dec. 31, 2014		16,202,689
Issuance of common stock for the purchase of Celleration, Inc.	15,207,500	$ 3,168	15,204,332	0
Issuance of common stock for the purchase of Celleration, Inc. (in shares)		3,168,229
Issuance of common stock for cash, net of issuance costs of $2,303,461	32,196,540	$ 7,582	32,188,958
Issuance of common stock for cash, net of issuance costs of $2,303,461 (in shares)		7,582,418
Exercise of common stock options	332,271	$ 76	332,195	0
Exercise of common stock options (in shares)		75,919
Cashless exercise of warrants	0	$ 9	(9)	0
Cashless exercise of warrants (in shares)		8,970
Extinguishment of warrant liability	31,498	$ 0	31,498	0
Stock-based compensation	6,580,379	$ 720	6,579,659	0
Stock-based compensation (in shares)		720,000
Net settlement on vesting of restricted stock awards	(471,169)	$ (89)	(471,080)	0
Net settlement on vesting of restricted stock awards (in shares)		(89,312)
Net loss	(21,783,992)	$ 0	0	(21,783,992)
Balance at Sep. 30, 2015	$ 54,604,258	$ 27,669	$ 146,403,295	$ (91,826,706)
Balance (in shares) at Sep. 30, 2015		27,668,913

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY [Parenthetical]	9 Months Ended
	Sep. 30, 2015USD ($)
Payments of Stock Issuance Costs	$ 2,303,461

CONDENSED CONSOLIDATED STATEME8

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Operating Activities
Net loss	$ (21,783,992)	$ (20,093,834)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,847,742	769,128
Amortization of deferred lease incentive	(6,253)	(6,253)
Deferred income tax (benefit) expense	(1,308,105)	10,500
Provision for doubtful accounts	66,248	0
Provision for inventory obsolescence	11,626	(65,493)
Stock-based compensation expense	6,580,379	8,822,925
Amortization of debt issuance and discount costs	326,118	0
Stock issued for services rendered	0	195,339
Change in value of warrant liability	(1,388,071)	19,324
Fair value adjustment of contingent consideration liability	957,732	194,034
Changes in operating assets and liabilities:
Accounts receivable	(610,453)	(547,206)
Inventory	(1,737,690)	(135,219)
Prepaid expenses and other current assets	(250,078)	(223,602)
Accounts payable	777,091	281,642
Accrued expenses and other current liabilities	(644,600)	599,209
Net Cash Used in Operating Activities	(17,162,306)	(10,179,506)
Investing Activities
Payment for distribution rights	0	(300,000)
Purchase of improvements and equipment	(230,549)	(6,596)
Acquisition of business, net of cash acquired	(14,947,813)	(1,999,526)
Net Cash Used in Investing Activities	(15,178,362)	(2,306,122)
Financing Activities
Net proceeds from issuance of common stock	32,196,540	14,372,503
Net proceeds from long-term debt	14,243,875	0
Proceeds from the exercise of stock options	332,271	1,243,867
Proceeds from the exercise of warrants	0	5,225,587
Payment of withholding taxes related to stock-based employee compensation	(471,169)	(569,285)
Net Cash Provided by Financing Activities	46,301,517	20,272,672
Net Increase in Cash and Cash Equivalents	13,960,849	7,787,044
Cash and Cash Equivalents - Beginning of period	16,770,879	12,100,544
Cash and Cash Equivalents - End of period	30,731,728	19,887,588
Supplemental Disclosure of Cash Flows Information
Cash paid during the period for Interest	435,077	384
Non-cash investing and financing activities:
Extinguishment of warrant liability due to cashless warrant exercise	31,498	672,632
2013 Bonus awarded in equity	0	307,189
Warrant exchange	0	49
Acquisition of business:
Current assets, excluding cash and cash equivalents	1,835,972	408,548
Intangibles	31,952,000	2,683,000
Goodwill	16,698,638	3,674,326
Liabilities assumed	(2,006,527)	(73,494)
Deferred tax liability	(2,754,770)	0
Contingent consideration	(15,570,000)	(2,700,000)
Issuance of common stock for acquisition	$ (15,207,500)	$ (1,992,854)

Description of Business and Bas

Description of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Description and Basis of Presentation [Text Block]	Description of Business and Basis of Presentation Alliqua BioMedical, Inc. (the “Company”) is a provider of advanced wound care solutions. The Company’s primary business strategy is to create superior outcomes for patients, providers, and partners through its hydrogel technology platform and licensed and proprietary products. The Company’s core businesses include advanced wound care and contract manufacturing. The Company seeks to leverage its proprietary hydrogel and licensed technology platform to add value to its own products and those of its partners. The condensed consolidated financial statements contained in this report are unaudited. In the opinion of management, the condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the Company’s financial position as of September 30, 2015 and results of operations for the three and nine months ended September 30, 2015, and cash flows for the nine months ended September 30, 2015. The accompanying condensed consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiary, AquaMed Technologies, Inc. All significant inter-company transactions and accounts have been eliminated in consolidation. Certain amounts in prior periods have been reclassified to conform to the current year presentation. Such reclassifications did not have a material effect on the Company’s financial condition or results of operations as previously reported. The Company’s significant accounting policies are disclosed in Note 2 — Summary of Significant Accounting Policies In July 2015, the FASB issued Accounting Standards Update 2015-11,” Inventory (Topic 330) Simplifying the Measurement of Inventory” (“ASU 2015-11”). Currently, all inventory is measured at the lower of cost or market. ASU 2015-11 changes the measurement principle for inventory from the lower of cost or market to the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business less reasonably predictable costs of completion, disposal and transportation. The standard is effective for annual reporting periods beginning after December 15, 2015, which for the Company will commence with the year beginning January 1, 2016. Prospective application is required. The Company does not believe the implementation of this standard will have a material impact on the Company’s condensed consolidated financial statements. In April 2015, the FASB issued Accounting Standards Update 2015-03, “Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs” (“ASU 2015-03”). ASU 2015-03 requires that debt issuance costs be presented as a direct deduction from the carrying amount of the related debt liability, consistent with the presentation of debt discounts. Prior to the issuance of ASU 2015-03, debt issuance costs were required to be presented as deferred charge assets, separate from the related debt liability. The Company early-adopted ASU 2015-03 during the three months ended June 30, 2015, and applied its provisions retrospectively. The adoption of ASU 2015-03 did not have an impact on the Company's condensed consolidated financial statements. In May 2014, the FASB issued a new revenue recognition standard entitled “Revenue from Contracts with Customers” under Accounting Standards Update 2014-09. The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. The standard is effective for annual reporting periods beginning after December 15, 2017, which for the Company will commence with the year beginning January 1, 2018. Earlier application is not permitted. Entities must adopt the new guidance using one of two retrospective application methods. The Company is currently evaluating the standard to determine the impact of its adoption on the consolidated financial statements. In June 2014, the FASB issued Accounting Standards Update 2014-12, “Compensation — Stock Compensation: Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period” (“ASU 2014-12”). ASU 2014-12 requires that a performance target that affects vesting of share-based payments and that could be achieved after the requisite service period be treated as a performance condition that affects vesting and as such, should not be reflected in estimating the grant-date fair value of the award. ASU 2014-12 is effective for annual and interim periods beginning after December 15, 2015. This standard is not expected to have a material effect on the Company’s financial position, results of operations or cash flows.

Net Loss Per Common Share

Net Loss Per Common Share	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	2. Net Loss Per Common Share Basic net loss per common share is computed based on the weighted average number of shares of common stock outstanding during the periods presented. Common stock equivalents, consisting of stock options, warrants and non-vested restricted stock, were not included in the calculation of the diluted loss per share because their inclusion would have been anti-dilutive. As of September 30, 2015 2014 Stock options 6,300,359 4,581,384 Warrants 3,372,550 2,675,121 Non-vested restricted stock 737,902 234,323 Total 10,410,811 7,490,828

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2015
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	3. Acquisitions Acquisition of Celleration, Inc. On May 29, 2015, the Company acquired all outstanding equity interest of Celleration, Inc. (“Celleration”), a medical device company focused on developing and commercializing the MIST Therapy® therapeutic ultrasound platform for the treatment of acute and chronic wounds for an aggregate purchase price of approximately $ 46.3 15.5 0.3 3,168,229 15,570,000 500,000 20 The estimated fair value of this liability is based on future sale projections of the MIST Therapy product and probability of receiving NICE approval. These fair value measurements were based on significant inputs not observed in the market and thus represented a Level 3 measurement. The contingent consideration is re-measured to fair value at each reporting date until the contingency is resolved, and those changes in fair value are recognized in earnings. 469,000 623,000 5,751,688 10,441,457 The assets and liabilities of the acquired business were included in the Company’s condensed consolidated balance sheet based upon estimated fair values on the date of acquisition as determined in a preliminary purchase price allocation, using available information and making assumptions management believes are reasonable. The Company is still in the process of completing its valuation of the assets, both tangible and intangible, and liabilities acquired. The condensed consolidated statements of operations include the results of the Celleration’s operations subsequent to the acquisition date. Consideration: Common stock $ 15,207,500 Cash paid 15,476,191 Fair value of contingent consideration 15,570,000 Total consideration 46,253,691 Cash 528,378 Trade receivables 876,590 Inventory 341,143 Other current assets 206,747 Improvements and equipment 411,492 Tradenames 3,601,000 Other indentifiable intangibles 27,143,000 Customer relationships 1,208,000 Goodwill 16,698,638 Accounts payable (308,615) Accrued expenses and other liabilities (1,697,912) Deferred tax liability (2,754,770) Net assets acquired $ 46,253,691 The Company recorded intangible assets of approximately $ 32.0 27.1 1.2 3.6 16.7 which is not expected to be deductible for tax purposes The Company funded the cash portion and related costs of the Celleration acquisition with the net proceeds received under the senior secured term loan described below in Note 7- Debt. Revenues included in the condensed consolidated statement of operations for each of the three and nine month periods ended September 30, 2015 from this acquisition for the period subsequent to the closing of the transaction was approximately $ 2,739,000 3,589,000 The net income or loss attributable to this acquisition cannot be identified on a stand-alone basis because it has been fully integrated into the Company's operations. During the three and nine month periods ended September 30, 2015, the Company incurred acquisition-related costs related to Celleration of approximately $ 15,000 2,875,000 Acquisition of Choice Therapeutics, Inc. On May 5, 2014, the Company acquired all outstanding equity interest of Choice Therapeutics, Inc., a provider of innovative wound care products using proprietary TheraBond 3D® Antimicrobial Barrier Systems. The Company’s initial cash payment for this acquisition was $ 2.0 2.0 5.0 The fair value of this liability was based on future sales projections of the product under various potential scenarios. These fair value measurements were based on significant inputs not observed in the market and thus represented a Level 3 measurement. The contingent consideration is re-measured to fair value at each reporting date until the contingency is resolved, and those changes in fair value are recognized in earnings. 116,000 335,000 Pro Forma Results The following unaudited pro forma financial information summarizes the results of operations for the three and nine months ended September 30, 2015 and 2014, as if the acquisitions had been completed as of January 1, 2014. The pro forma results were calculated applying the Company’s accounting policies and include the effects of adjustments related to the amortization charges from the acquired intangibles and long-term debt. Three Months Ended September 30, 2015 Nine Months Ended September 30, 2015 2014 2015 2014 Revenues $ 5,013,835 $ 3,843,840 $ 14,352,966 $ 10,398,689 Net loss $ (7,132,665) $ (7,034,828) $ (26,583,343) $ (27,449,550) Net loss per share $ (0.26) $ (0.37) $ (1.13) $ (1.58)

Inventory

Inventory	9 Months Ended
	Sep. 30, 2015
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	4. Inventory September 30, 2015 December 31, 2014 Raw materials $ 265,737 $ 197,514 Work in process 659,256 489,431 Finished goods 2,566,682 725,897 Less: Inventory reserve (12,720) (1,094) Total $ 3,478,955 $ 1,411,748

Intangible Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	5. Intangible Assets September 30, 2015 Useful Life Gross Accumulated Net Technology 10 $ 32,539,000 $ (3,244,200) $ 29,294,800 Customer relationships 9-12 1,984,000 (401,304) 1,582,696 Distribution rights 5.27 400,000 (154,023) 245,977 Tradename 3 111,000 (52,417) 58,583 Tradename Indefinite 3,601,000 - 3,601,000 Non-compete 1 208,333 (208,333) - $ 38,843,333 $ (4,060,277) $ 34,783,056 December 31, 2014 Useful Life Gross Accumulated Net Technology 10 $ 5,396,000 $ (1,934,733) $ 3,461,267 Customer relationships 9-12 776,000 (308,871) 467,129 Distribution rights 5.27 400,000 (96,880) 303,120 Tradename 3 111,000 (24,667) 86,333 Non-compete 1 208,333 (138,889) 69,444 $ 6,891,333 $ (2,504,040) $ 4,387,293 Amortization expense attributable to intangible assets for the three months ended September 30, 2015 and 2014 was $ 889,362 232,670 1,556,237 529,847 2,445,598 3,557,446 3,532,779 3,518,804 3,169,256

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2015
Accrued Liabilities, Current [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	6. Accrued Expenses September 30, 2015 December 31, 2014 Salaries, benefits and incentive compensation $ 1,877,363 $ 1,528,229 Professional fees 545,465 228,426 Royalty fees 423,786 100,537 Deferred revenue 94,851 78,523 Deferred lease incentive liability 8,337 8,337 Other 171,370 123,807 Total accrued expenses and other current liabilities $ 3,121,172 $ 2,067,859

Debt

Debt	9 Months Ended
	Sep. 30, 2015
Debt Instruments [Abstract]
Long-term Debt [Text Block]	Debt Senior Secured Term Loan Facility On May 29, 2015, simultaneously with and related to the closing of the Celleration acquisition, the Company entered into a Credit Agreement and Guaranty (the “Credit Agreement”) with Perceptive Credit Opportunities Fund, L.P. (“Perceptive”). The Credit Agreement provided a senior secured term loan in a single borrowing to the Company in the principal amount of $ 15.5 225,000 1,256,125 72,258 98,427 In connection with the entry into the Credit Agreement, a five-year warrant 750,000 0.001 5.5138 2,682,710 168,932 227,691 The Credit Agreement requires the Company to prepay the outstanding principal amount of the term loan with 100% of the net cash proceeds received from specified asset sales, issuances or sales of equity and incurrences of borrowed money indebtedness, subject to certain exceptions. The Company is required to pay an exit fee when the term loan is paid in full equal to the greater of 1% of the outstanding principal balance immediately prior to the final payment and $100,000. The Credit Agreement contains customary affirmative and negative covenants and events of default for a secured financing arrangement, including limitations on additional indebtedness, liens, asset sales and acquisitions, among others. In addition to other customary events of default, any termination of that certain License, Marketing and Development Agreement between the Company and CCT, as amended, will constitute an event of default under the Credit Agreement. September 30, 2015 Long-term debt $ 15,500,000 Unamortized debt issuance and discount costs (3,612,717) Long-term debt, net $ 11,887,283

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Commitments and Contingencies License Agreement On July 15, 2011, the Company entered into a license agreement with Noble Fiber Technologies, LLC, whereby the Company has the exclusive right and license to manufacture and distribute “SilverSeal Hydrogel Wound Dressings” and “SilverSeal Hydrocolloid Wound Dressings”. The license is granted for ten years with an option to be extended for consecutive renewal periods of two years after the initial term. Royalties are to be paid equal to 9.75 500,000 600,000 125,000 100,000 375,000 300,000 810 372,275 The Company expects to incur the minimum royalty in 2015 and 2016. Sorbion Distributor Agreement In September 2013, the Company entered into a distributor agreement (the “Sorbion Agreement”) with Sorbion GmbH & Co KG, pursuant to which the Company became the exclusive distributor of sorbion sachet S, sorbion sana and new products with hydrokinetic fibers as primary dressings in the United States, Canada and Latin America, subject to certain exceptions. The term of the agreement ends on December 31, 2018. Sorbion assigned its rights and obligations of the Sorbion Agreement to BSN Medical, Inc. (“BSN ”), an affiliate of Sorbion, 1,100,000 The Company has met the minimum purchase amount requirement for 2015. Calendar Year Minimum Annual Purchase Amount 2016 2,500,000 Euros 2017 4,000,000 Euros If the Company fails to purchase products in amounts that meet or exceed the minimum annual purchase amount for a calendar year, it may cure such minimum purchase failure by paying BSN in cash an amount equal to the minimum annual purchase amount for such calendar year less the amount the Company paid to BSN for the products purchased for such calendar year. If the Company does not cure a minimum purchase failure with a makeup payment for a calendar year, BSN may terminate the Company’s exclusivity with respect to the products and grant the Company non-exclusive rights with respect to the products. If the Company does not cure a minimum purchase failure for two subsequent calendar years, BSN may terminate the agreement. The Company will not be required to meet the minimal annual purchase amount if BSN fails to supply the Company with the products in accordance with the agreement. BSN may also terminate the Company’s exclusivity with respect to the products if the Company does not cure a material breach of the agreement within 30 days. The Company has the right to use the trademarks related to the products. The Company has the ability to sell the products under their respective trademarked names and at prices determined by the Company. The Company is eligible for certain discounts with respect to the purchase and shipping of the products if its orders of the products are above certain amounts. Celgene License, Marketing and Development and Supply Agreement In November 2013, the Company entered into a License, Marketing and Development Agreement (the “License Agreement”) with Anthrogenesis Corporation, d/b/a Celgene Cellular Therapeutics (“CCT”), an affiliate of Celgene Corporation (“Celgene”), pursuant to which CCT granted the Company an exclusive, royalty-bearing license in its intellectual property for certain placental based products, including ECM, an extracellularmatrix derived from the human placenta, and Biovance®, CCT’s proprietary wound coverings produced from decellularized, dehydrated human amniotic membrane, to develop and commercialize ECM and Biovance in the United States. Following the commencement of commercial sales of the licensed products, the Company will pay CCT annual license fees, designated amounts when certain milestone events occur and royalties on all sales of licensed products, with such amounts being variable and contingent on various factors. The initial term of the License Agreement ends on November 14, 2023, unless sooner terminated pursuant to the termination rights under the License Agreement, and will extend for additional two-year terms unless either party gives written notice within a specified period prior to the end of a term. The License Agreement may be terminated (i) by CCT if the Company or any of its affiliates challenges the validity, enforceability or scope of certain enumerated CCT patents anywhere in the world; (ii) by either party if there is a final decree that a licensed product infringed on the intellectual property of a third party; (iii) by either party for breach of the License Agreement, if the breach is not cured within a specified period after receiving written notice of the breach; or (iv) by either party if the other party is the subject of insolvency proceedings, either voluntary or involuntary. In addition, the License Agreement is terminable on a product-by-product basis, and not with respect to the entire License Agreement (i) by CCT in the second year of the License Agreement, and by either CCT or the Company in the third year of the License Agreement and beyond, if the Company fails to meet certain sales thresholds and (ii) by either party upon written notice if outside legal counsel recommends discontinuance of commercialization of a product because of significant safety, legal, or economic risk as a result of a claim, demand or action or as a result of a change in the interpretation of law by a governmental or regulatory authority. The License Agreement also contains mutual confidentiality and indemnification obligations for the Company and CCT. In September 2014, the Company entered into a First Amendment to the License Agreement (the “Amended License Agreement”), pursuant to which the Company received the right to market Biovance for podiatric and orthopedic applications. The Amended License Agreement also amends certain terms and the related schedule for milestone payments to CCT. In May 2015, the Company amended its exclusive licensing agreement with CCT, which granted the Company the right to develop and market CCT’s connective tissue matrix product (“CTM”). In November 2013, the Company also entered into a Supply Agreement (the “Biovance Supply Agreement”) with CCT, pursuant to which CCT shall supply the Company with the Company’s entire requirements of Biovance for distribution and sale in the United States. The Biovance Supply Agreement will be terminated automatically upon the termination of the License Agreement and may otherwise be terminated (i) by CCT upon six months’ prior written notice, (ii) by the Company upon six months’ prior written notice if CCT fails to deliver at least a specified portion of a firm purchase order by the required delivery date specified in the order on at least a specified number of occasions in a specified period; (iii) by either party for breach of the Biovance Supply Agreement, if the breach is not cured within a specified period after receiving written notice of the breach; or (iv) by either party if the other party is the subject of insolvency proceedings, either voluntary or involuntary. On April 10, 2014, the Company and CCT entered into an amendment to the Biovance Supply Agreement in order to amend the pricing schedule. In April 2014, the Company entered into a Supply Agreement (the “ECM Supply Agreement”) with CCT, pursuant to which CCT shall, as soon as reasonably practicable after the date that CCT obtains regulatory clearance or approval in the United States for any of CCT’s extracellular matrix products derived from the human placenta (each an “ECM”), supply and sell to the Company all of the Company’s requirements of ECM, in finished form and final packaging, for exploitation in the United States under the License Agreement. The ECM Supply Agreement will automatically terminate upon the termination or expiration of the License Agreement and may otherwise be terminated (i) by CCT upon six months’ prior written notice, (ii) by the Company upon six months’ prior written notice if CCT fails to deliver at least a specified portion of a firm purchase order by the required delivery date specified in the order on at least a specified number of occasions in a specified period; (iii) by either party for breach of the ECM Supply Agreement, if the breach is not cured within a specified period after receiving written notice of the breach; or (iv) by either party if the other party is the subject of insolvency proceedings, either voluntary or involuntary. The ECM Supply Agreement also contains mutual confidentiality and indemnification obligations for the Company and CCT. Litigation, Claims and Assessments The Company is subject to periodic lawsuits, investigations and claims that arise in the ordinary course of business. The Company is not party to any material litigation as of September 30, 2015.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2015
Stockholders Equity Note [Abstract]
Stockholders Equity Note Disclosure [Text Block]	9. Stockholders’ Equity Common Stock Issuances On May 4, 2015, the Company closed an underwritten public offering of 7,582,418 4.55 32,196,540 2011 Plan The Company maintains the 2011 Long-Term Incentive Plan (the “2011 Plan”) that provides for the granting of stock options, RSUs, restricted stock and other awards to employees, directors and others. A total of 1,828,571 117,336 2014 Plan On April 10, 2014 and September 5, 2014, the Company’s Board of Directors and the Company’s shareholders approved the 2014 Long-Term Incentive Plan (the “2014 Plan”), respectively. The 2014 Plan provides for the granting of stock options, RSUs, restricted stock and other awards to employees, directors and others. On February 26, 2015 and May 6, 2015, the Company’s Board of Directors and the Company’s shareholders approved an amendment to the 2014 Plan to increase the total number of shares of common stock authorized for issuance under the 2014 Plan by an additional 3,500,000 5,500,000 2,931,488 Stock-Based Compensation Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Options $ 1,564,191 $ 1,450,527 $ 4,543,275 $ 6,361,366 Warrants - 13,496 - 208,530 Restricted stock units - - - 180,715 Restricted stock 693,176 378,442 2,037,104 2,267,653 Total stock-based compensation $ 2,257,367 $ 1,842,465 $ 6,580,379 $ 9,018,264 For the three and nine months ended September 30, 2015, $ 91,259 273,127 2,166,108 6,307,252 63,331 143,184 1,779,134 8,875,080 Restricted Stock Issuance Grantee Shares Vesting Grant Date Date Type Issued Term Value 02/06/15 Officers 600,000 [1] $ 3,738,000 06/15/15 Officer 120,000 [2] 630,000 2015 - Restricted Stock - Total 720,000 $ 4,368,000 [1] Vests in three equal annual installments, with one-third vesting on each of February 6, 2016, February 6, 2017 and February 6, 2018. [2] Vests in four equal installments, with one-fourth vesting on the date of grant and one-fourth vesting on each of June 15, 2016, June 15, 2017 and June 15, 2018. As of September 30, 2015, there was $ 2,654,114 1.6 Number of Weighted Total Grant Non-vested, December 31, 2014 188,149 $ 7.03 $ 1,322,096 Granted 720,000 6.07 4,368,000 Vested (170,247) 6.70 (1,141,294) Forfeited - - - Non-vested, September 30, 2015 737,902 $ 6.16 $ 4,548,802 Warrants There were no compensatory warrants issued during the nine months ended September 30, 2015. During the nine months ended September 30, 2015, the Company issued an aggregate of 8,970 15,999 2.19 44,906 As of September 30, 2015, there was no unrecognized stock-based compensation expense related to compensatory warrants. Number of Weighted Weighted Intrinsic Value Outstanding, December 31, 2014 2,675,121 $ 5.76 Issued 750,000 5.51 Exercised (15,999) 2.19 Cancelled (36,572) 7.88 Outstanding, September 30, 2015 3,372,550 $ 5.70 3.3 $ 101,864 Exercisable, September 30, 2015 3,372,550 $ 5.70 3.3 $ 101,864 The following table presents information related to warrants at September 30, 2015: Warrants Outstanding Warrants Exercisable Exercise Price Outstanding Weighted Exercisable $ 2.19 92,573 2.0 92,573 3.02 74,286 1.4 74,286 3.50 2,286 1.6 2,286 4.24 780,191 2.7 780,191 4.38 188,444 3.1 188,444 4.81 8,889 3.1 8,889 5.51 750,000 4.7 750,000 5.69 1,040,880 3.1 1,040,880 8.75 7,143 0.4 7,143 10.50 427,858 3.5 427,858 3,372,550 3.3 3,372,550 As of September 30, 2015, warrants to purchase an aggregate of 816,287 5.24 Stock Options Options – 2015 Grants During the nine months ended September 30, 2015, ten-year options to purchase an aggregate of 1,806,000 4.06 6.23 7,711,629 1,719,000 87,000 4,500 90,000 1,711,500 Options – Summary Data Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Risk free interest rate 1.78 % 1.96 % 1.72 % 1.92 % Expected term (years) 6.00 5.98 5.96 5.94 Expected volatility 93.70 % 100.56 % 97.37 % 102.36 % Expected dividends 0.00 % 0.00 % 0.00 % 0.00 % The risk-free interest rate is based on rates of treasury securities with the same expected term as the options. The Company uses the "simplified method" to calculate the expected term of employee and director stock-based options. The expected term used for consultants is the contractual life. The Company is utilizing an expected volatility figure based on a review of the Company’s historical volatility, over a period of time, equivalent to the expected life of the instrument being valued. The expected dividend yield is based upon the fact that the Company has not historically paid dividends, and does not expect to pay dividends in the near future. Option forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period. This estimate will be adjusted periodically based on the extent to which actual option forfeitures differ, or are expected to differ, from the previous estimate, when it is material. The Company estimated forfeitures related to options at annual rates ranging from 0 5 The weighted average estimated fair value per share of the options granted during the three and nine months ended September 30, 2015 was $ 3.78 4.27 The weighted average estimated fair value per share of the options granted during the three and nine months ended September 30, 2014 was $ 4.29 6.21 During the nine months ended September 30, 2015, the Company issued an aggregate of 75,919 75,919 332,271 4.38 85,798 As of September 30, 2015, there was $ 7,202,954 1.6 5,132 Number of Weighted Weighted Intrinsic Value Outstanding, December 31, 2014 4,817,660 $ 6.56 Granted 1,806,000 5.50 Exercised (75,919) 4.38 Forfeited (247,382) 6.27 Outstanding, September 30, 2015 6,300,359 $ 6.29 7.6 $ - Exerciseable, September 30, 2015 3,077,608 $ 6.06 6.4 $ - Options Outstanding Options Exercisable Range of Weighted Outstanding Weighted Average Weighted Exercisable $3.28-$3.99 $ 3.37 413,971 $ 3.36 7.6 403,971 $4.00-$4.99 4.58 1,553,982 4.39 3.7 833,342 $5.00-$5.99 5.26 723,427 5.45 6.1 220,523 $6.00-$6.99 6.59 2,258,629 6.77 7.8 958,137 $7.00-$7.99 7.75 31,000 7.75 8.6 10,333 $8.00-$8.99 8.74 790,898 8.74 6.9 481,245 $9.00-$9.99 9.00 264,833 9.00 7.1 113,828 $10.00-$26.69 10.96 263,619 11.01 7.5 56,229 6,300,359 6.4 3,077,608

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	10. Income Taxes The Company acquired all the outstanding equity interest of Celleration on May 29, 2015. The Company’s preliminary allocation of purchase price for this acquisition is included in Note 3 – Acquisitions, and includes an approximately $ 2.8 1.3 1.4

Related Party

Related Party	9 Months Ended
	Sep. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	11. Related Party The Company has entered into several agreements with CCT, a wholly-owned subsidiary of Celgene Corporation, as described in Note 8 – Commitments and Contingencies. Celgene is an affiliate of the Company. Two executives of Celgene are on the Company’s board of directors, one of whom is the chief executive officer of CCT. On May 6, 2015, the Company amended its exclusive licensing agreement with CCT, which granted the Company the right to develop and market CCT’s connective tissue matrix product (“CTM”). On January 6, 2014, the Company entered into an option cancellation and release agreement with two former directors, pursuant to which each of the parties agreed to cancel options previously granted to purchase 278,096 6.34 9.19 194,667 98,915

Concentration of Risk

Concentration of Risk	9 Months Ended
	Sep. 30, 2015
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	12. Concentration of Risk Revenue for the three months ended September 30, 2015 and 2014, and accounts receivable as of September 30, 2015 from the Company’s largest customer, a contract manufacturing customer, was as follows: % of Total Revenue Accounts Receivable Customer 2015 2014 September 30, 2015 A 6 % 22 % 5 % Revenue for the nine months ended September 30, 2015 and 2014 from the Company’s largest customer, a contract manufacturing customer, was as follows: % of Total Revenue Customer 2015 2014 A 11 % 31 %

Fair Value Measurement

Fair Value Measurement	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	Fair Value Measurement Fair value is defined as the price that would be received upon selling an asset or the price paid to transfer a liability on the measurement date. It focuses on the exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between willing market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair values are as follows: Level 1: Observable prices in active markets for identical assets and liabilities. Level 2: Observable inputs other than quoted prices in active markets for identical assets and liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities. During the nine months ended September 30, 2015, a warrant to purchase an aggregate of 9,142 31,498 0 3,914 98.25 0.96 2.52 0.00 During the nine months ended September 30, 2015, in connection with the Credit Agreement, a five-year warrant to purchase 750,000 5.5138 2,682,710 98.25 1.49 5.00 0.00 On September 30, 2015, the Company recomputed the fair value of its warrant liability of warrants to purchase an aggregate of 816,287 1,567,364 93.70 1.37 0.64 4.67 2.11 0.00 1,466,208 1,384,157 Nine Months Ended September 30, 2015 2014 Warrant Liabilities Beginning balance $ 304,223 $ 933,465 Change in fair value of warrant liability (1,388,071) 19,324 Value of warrants issued 2,682,710 - Value of warrants exercised (31,498) (672,632) Ending balance $ 1,567,364 $ 280,157 Nine Months Ended September 30, 2015 2014 Contingent Consideration Beginning balance $ 2,931,598 $ - Initial fair value of contingent consideration 15,570,000 2,700,000 Change in fair value of contingent consideration 957,732 194,034 Ending balance $ 19,459,330 $ 2,894,034 September 30, 2015 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 1,567,364 Contingent consideration - - 19,459,330 Total liabilities $ - $ - $ 21,026,694 December 31, 2014 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 304,223 Contingent consideration - - 2,931,598 Total liabilities $ - $ - $ 3,235,821 Warrants that contain exercise reset provisions and contingent consideration liabilities are Level 3 derivative liabilities measured at fair value on a recurring basis using pricing models for which at least one significant assumption is unobservable as defined in ASC 820. The fair value of contingent consideration liabilities that was classified as Level 3 in the table above was estimated using a discounted cash flow technique with significant inputs that are not observable in the market and thus represents a Level 3 fair value measurement as defined in ASC 820. The significant inputs in the Level 3 measurement not supported by market activity include the probability assessments of expected future cash flows related to the acquisitions, appropriately discounted considering the uncertainties associated with the obligation, and as calculated in accordance with the terms of the acquisition agreements. The development and determination of the unobservable inputs for Level 3 fair value measurements and the fair value calculations are the responsibility of the Company’s chief financial officer and are approved by the chief executive officer.

Description of Business and B22

Description of Business and Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The condensed consolidated financial statements contained in this report are unaudited. In the opinion of management, the condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the Company’s financial position as of September 30, 2015 and results of operations for the three and nine months ended September 30, 2015, and cash flows for the nine months ended September 30, 2015.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The accompanying condensed consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiary, AquaMed Technologies, Inc. All significant inter-company transactions and accounts have been eliminated in consolidation.
Reclassification, Policy [Policy Text Block]	Reclassifications Certain amounts in prior periods have been reclassified to conform to the current year presentation. Such reclassifications did not have a material effect on the Company’s financial condition or results of operations as previously reported.
Significant Accounting Policies and Estimates [Policy Text Block]	Significant Accounting Policies and Estimates The Company’s significant accounting policies are disclosed in Note 2 — Summary of Significant Accounting Policies
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In July 2015, the FASB issued Accounting Standards Update 2015-11,” Inventory (Topic 330) Simplifying the Measurement of Inventory” (“ASU 2015-11”). Currently, all inventory is measured at the lower of cost or market. ASU 2015-11 changes the measurement principle for inventory from the lower of cost or market to the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business less reasonably predictable costs of completion, disposal and transportation. The standard is effective for annual reporting periods beginning after December 15, 2015, which for the Company will commence with the year beginning January 1, 2016. Prospective application is required. The Company does not believe the implementation of this standard will have a material impact on the Company’s condensed consolidated financial statements. In April 2015, the FASB issued Accounting Standards Update 2015-03, “Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs” (“ASU 2015-03”). ASU 2015-03 requires that debt issuance costs be presented as a direct deduction from the carrying amount of the related debt liability, consistent with the presentation of debt discounts. Prior to the issuance of ASU 2015-03, debt issuance costs were required to be presented as deferred charge assets, separate from the related debt liability. The Company early-adopted ASU 2015-03 during the three months ended June 30, 2015, and applied its provisions retrospectively. The adoption of ASU 2015-03 did not have an impact on the Company's condensed consolidated financial statements. In May 2014, the FASB issued a new revenue recognition standard entitled “Revenue from Contracts with Customers” under Accounting Standards Update 2014-09. The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. The standard is effective for annual reporting periods beginning after December 15, 2017, which for the Company will commence with the year beginning January 1, 2018. Earlier application is not permitted. Entities must adopt the new guidance using one of two retrospective application methods. The Company is currently evaluating the standard to determine the impact of its adoption on the consolidated financial statements. In June 2014, the FASB issued Accounting Standards Update 2014-12, “Compensation — Stock Compensation: Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period” (“ASU 2014-12”). ASU 2014-12 requires that a performance target that affects vesting of share-based payments and that could be achieved after the requisite service period be treated as a performance condition that affects vesting and as such, should not be reflected in estimating the grant-date fair value of the award. ASU 2014-12 is effective for annual and interim periods beginning after December 15, 2015. This standard is not expected to have a material effect on the Company’s financial position, results of operations or cash flows.

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The total common shares issuable upon the exercise of stock options, warrants and non-vested restricted stock are as follows: As of September 30, 2015 2014 Stock options 6,300,359 4,581,384 Warrants 3,372,550 2,675,121 Non-vested restricted stock 737,902 234,323 Total 10,410,811 7,490,828

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2015
Business Acquisition, Pro Forma Information [Table Text Block]	The unaudited pro forma information does not purport to be indicative of the results that would have been obtained if the acquisitions had actually occurred at the beginning of the year prior to acquisition, nor of the results that may be reported in the future. Three Months Ended September 30, 2015 Nine Months Ended September 30, 2015 2014 2015 2014 Revenues $ 5,013,835 $ 3,843,840 $ 14,352,966 $ 10,398,689 Net loss $ (7,132,665) $ (7,034,828) $ (26,583,343) $ (27,449,550) Net loss per share $ (0.26) $ (0.37) $ (1.13) $ (1.58)
Acquisition of Celleration, Inc [Member]
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	The Company’s preliminary allocation of purchase price for this acquisition is included in the table below, which summarizes the estimated fair value of the assets acquired and liabilities assumed at the date of acquisition: Consideration: Common stock $ 15,207,500 Cash paid 15,476,191 Fair value of contingent consideration 15,570,000 Total consideration 46,253,691 Cash 528,378 Trade receivables 876,590 Inventory 341,143 Other current assets 206,747 Improvements and equipment 411,492 Tradenames 3,601,000 Other indentifiable intangibles 27,143,000 Customer relationships 1,208,000 Goodwill 16,698,638 Accounts payable (308,615) Accrued expenses and other liabilities (1,697,912) Deferred tax liability (2,754,770) Net assets acquired $ 46,253,691

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventory consists of the following: September 30, 2015 December 31, 2014 Raw materials $ 265,737 $ 197,514 Work in process 659,256 489,431 Finished goods 2,566,682 725,897 Less: Inventory reserve (12,720) (1,094) Total $ 3,478,955 $ 1,411,748

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2015
Finite-Lived Intangible Assets, Net [Abstract]
Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]	The gross carrying amount and accumulated amortization of intangible assets are as follows: September 30, 2015 Useful Life Gross Accumulated Net Technology 10 $ 32,539,000 $ (3,244,200) $ 29,294,800 Customer relationships 9-12 1,984,000 (401,304) 1,582,696 Distribution rights 5.27 400,000 (154,023) 245,977 Tradename 3 111,000 (52,417) 58,583 Tradename Indefinite 3,601,000 - 3,601,000 Non-compete 1 208,333 (208,333) - $ 38,843,333 $ (4,060,277) $ 34,783,056 December 31, 2014 Useful Life Gross Accumulated Net Technology 10 $ 5,396,000 $ (1,934,733) $ 3,461,267 Customer relationships 9-12 776,000 (308,871) 467,129 Distribution rights 5.27 400,000 (96,880) 303,120 Tradename 3 111,000 (24,667) 86,333 Non-compete 1 208,333 (138,889) 69,444 $ 6,891,333 $ (2,504,040) $ 4,387,293

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2015
Accrued Liabilities, Current [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses consist of the following: September 30, 2015 December 31, 2014 Salaries, benefits and incentive compensation $ 1,877,363 $ 1,528,229 Professional fees 545,465 228,426 Royalty fees 423,786 100,537 Deferred revenue 94,851 78,523 Deferred lease incentive liability 8,337 8,337 Other 171,370 123,807 Total accrued expenses and other current liabilities $ 3,121,172 $ 2,067,859

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2015
Debt Instruments [Abstract]
Schedule of Debt [Table Text Block]	Debt consists of the following: September 30, 2015 Long-term debt $ 15,500,000 Unamortized debt issuance and discount costs (3,612,717) Long-term debt, net $ 11,887,283

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Long-term Purchase Commitment [Table Text Block]	If the exchange rate is five percent greater or less than 1.10, the rate will be rounded as necessary so that it is no more than five percent greater or five percent less. Calendar Year Minimum Annual Purchase Amount 2016 2,500,000 Euros 2017 4,000,000 Euros

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2015
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	The following table summarizes stock-based compensation expense: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Options $ 1,564,191 $ 1,450,527 $ 4,543,275 $ 6,361,366 Warrants - 13,496 - 208,530 Restricted stock units - - - 180,715 Restricted stock 693,176 378,442 2,037,104 2,267,653 Total stock-based compensation $ 2,257,367 $ 1,842,465 $ 6,580,379 $ 9,018,264
Nonvested Restricted Stock Shares Activity [Table Text Block]	The following table summarizes the restricted stock issued as compensation during the nine months ended September 30, 2015: Issuance Grantee Shares Vesting Grant Date Date Type Issued Term Value 02/06/15 Officers 600,000 [1] $ 3,738,000 06/15/15 Officer 120,000 [2] 630,000 2015 - Restricted Stock - Total 720,000 $ 4,368,000 [1] Vests in three equal annual installments, with one-third vesting on each of February 6, 2016, February 6, 2017 and February 6, 2018. [2] Vests in four equal installments, with one-fourth vesting on the date of grant and one-fourth vesting on each of June 15, 2016, June 15, 2017 and June 15, 2018.
Schedule of Nonvested Share Activity [Table Text Block]	A summary of common stock award activity during the nine months ended September 30, 2015 is presented below: Number of Weighted Total Grant Non-vested, December 31, 2014 188,149 $ 7.03 $ 1,322,096 Granted 720,000 6.07 4,368,000 Vested (170,247) 6.70 (1,141,294) Forfeited - - - Non-vested, September 30, 2015 737,902 $ 6.16 $ 4,548,802
Warrant [Member]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the warrant activity during the nine months ended September 30, 2015 is presented below: Number of Weighted Weighted Intrinsic Value Outstanding, December 31, 2014 2,675,121 $ 5.76 Issued 750,000 5.51 Exercised (15,999) 2.19 Cancelled (36,572) 7.88 Outstanding, September 30, 2015 3,372,550 $ 5.70 3.3 $ 101,864 Exercisable, September 30, 2015 3,372,550 $ 5.70 3.3 $ 101,864
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	Warrants Outstanding Warrants Exercisable Exercise Price Outstanding Weighted Exercisable $ 2.19 92,573 2.0 92,573 3.02 74,286 1.4 74,286 3.50 2,286 1.6 2,286 4.24 780,191 2.7 780,191 4.38 188,444 3.1 188,444 4.81 8,889 3.1 8,889 5.51 750,000 4.7 750,000 5.69 1,040,880 3.1 1,040,880 8.75 7,143 0.4 7,143 10.50 427,858 3.5 427,858 3,372,550 3.3 3,372,550
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	In applying the Black-Scholes option pricing model to stock options granted, the Company used the following weighted average assumptions: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Risk free interest rate 1.78 % 1.96 % 1.72 % 1.92 % Expected term (years) 6.00 5.98 5.96 5.94 Expected volatility 93.70 % 100.56 % 97.37 % 102.36 % Expected dividends 0.00 % 0.00 % 0.00 % 0.00 %
Employee Stock Option [Member]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the stock option activity during the nine months ended September 30, 2015 is presented below: Number of Weighted Weighted Intrinsic Value Outstanding, December 31, 2014 4,817,660 $ 6.56 Granted 1,806,000 5.50 Exercised (75,919) 4.38 Forfeited (247,382) 6.27 Outstanding, September 30, 2015 6,300,359 $ 6.29 7.6 $ - Exerciseable, September 30, 2015 3,077,608 $ 6.06 6.4 $ -
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following table presents information related to stock options at September 30, 2015: Options Outstanding Options Exercisable Range of Weighted Outstanding Weighted Average Weighted Exercisable $3.28-$3.99 $ 3.37 413,971 $ 3.36 7.6 403,971 $4.00-$4.99 4.58 1,553,982 4.39 3.7 833,342 $5.00-$5.99 5.26 723,427 5.45 6.1 220,523 $6.00-$6.99 6.59 2,258,629 6.77 7.8 958,137 $7.00-$7.99 7.75 31,000 7.75 8.6 10,333 $8.00-$8.99 8.74 790,898 8.74 6.9 481,245 $9.00-$9.99 9.00 264,833 9.00 7.1 113,828 $10.00-$26.69 10.96 263,619 11.01 7.5 56,229 6,300,359 6.4 3,077,608

Concentration of Risk (Tables)

Concentration of Risk (Tables)	9 Months Ended
	Sep. 30, 2015
Risks and Uncertainties [Abstract]
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	Revenue for the three months ended September 30, 2015 and 2014, and accounts receivable as of September 30, 2015 from the Company’s largest customer, a contract manufacturing customer, was as follows: % of Total Revenue Accounts Receivable Customer 2015 2014 September 30, 2015 A 6 % 22 % 5 % Revenue for the nine months ended September 30, 2015 and 2014 from the Company’s largest customer, a contract manufacturing customer, was as follows: % of Total Revenue Customer 2015 2014 A 11 % 31 %

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table sets forth a summary of the changes in the fair value of Level 3 warrant liabilities that are measured at fair value on a recurring basis: Nine Months Ended September 30, 2015 2014 Warrant Liabilities Beginning balance $ 304,223 $ 933,465 Change in fair value of warrant liability (1,388,071) 19,324 Value of warrants issued 2,682,710 - Value of warrants exercised (31,498) (672,632) Ending balance $ 1,567,364 $ 280,157 Nine Months Ended September 30, 2015 2014 Contingent Consideration Beginning balance $ 2,931,598 $ - Initial fair value of contingent consideration 15,570,000 2,700,000 Change in fair value of contingent consideration 957,732 194,034 Ending balance $ 19,459,330 $ 2,894,034
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Assets and liabilities measured at fair value on a recurring or nonrecurring basis are as follows: September 30, 2015 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 1,567,364 Contingent consideration - - 19,459,330 Total liabilities $ - $ - $ 21,026,694 December 31, 2014 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 304,223 Contingent consideration - - 2,931,598 Total liabilities $ - $ - $ 3,235,821

Net Loss Per Common Share (Deta

Net Loss Per Common Share (Details) - shares	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	10,410,811	7,490,828
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,300,359	4,581,384
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,372,550	2,675,121
Non-vested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	737,902	234,323

Acquisitions (Details)

Acquisitions (Details) - USD ($)	1 Months Ended	9 Months Ended
	May. 29, 2015	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Consideration:
Fair value of contingent consideration		$ 15,570,000	$ 2,700,000
Goodwill		20,798,933		$ 4,100,295
Acquisition of Celleration, Inc [Member]
Consideration:
Common stock	$ 15,207,500
Cash paid	15,476,191
Fair value of contingent consideration	15,570,000
Total consideration	46,253,691
Cash	528,378
Trade receivables	876,590
Inventory	341,143
Other current assets	206,747
Improvements and equipment	411,492
Goodwill	16,698,638
Accounts payable	(308,615)
Accrued expenses and other liabilities	(1,697,912)
Deferred tax liability	(2,754,770)	$ (1,400,000)
Net assets acquired	46,253,691
Acquisition of Celleration, Inc [Member] | Trade Names [Member]
Consideration:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	3,601,000
Acquisition of Celleration, Inc [Member] | Other Identifiable Intangibles [Member]
Consideration:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	27,143,000
Acquisition of Celleration, Inc [Member] | Customer Relationships [Member]
Consideration:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	$ 1,208,000

Acquisitions (Details 1)

Acquisitions (Details 1) - Choice Therapeutics, Inc. [Member] - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Business Acquisition [Line Items]
Revenues	$ 5,013,835	$ 3,843,840	$ 14,352,966	$ 10,398,689
Net loss	$ (7,132,665)	$ (7,034,828)	$ (26,583,343)	$ (27,449,550)
Net loss per share	$ (0.26)	$ (0.37)	$ (1.13)	$ (1.58)

Acquisitions (Details Textual)

Acquisitions (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	May. 29, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	May. 05, 2014
Business Acquisition [Line Items]
Business Combination, Acquisition Related Costs		$ 15,000	$ 61,330	$ 2,875,586	$ 546,970
Amortization of Intangible Assets		889,362	$ 232,670	1,556,237	529,847
Working Capital	$ 300,000
Business Combination, Contingent Consideration, at Fair Value				15,570,000	$ 2,700,000
Goodwill		20,798,933		$ 20,798,933		$ 4,100,295
Business Combination, Contingent Consideration Arrangements, Description				The Company has agreed to pay contingent consideration of three and one half times revenue from acquired MIST Therapy products in excess of certain revenue targets for the fiscal years ending December 31, 2015 and 2016, payable in equal amounts of cash and the Companys common stock.
Business Combination, Contingent Consideration, Liability, Current		5,751,688		$ 5,751,688		0
Business Combination, Contingent Consideration, Liability, Noncurrent		13,707,642		$ 13,707,642		$ 2,931,598
Common Stock [Member]
Business Acquisition [Line Items]
Stock Issued During Period, Shares, Acquisitions				3,168,229
Choice Therapeutics, Inc. [Member]
Business Acquisition [Line Items]
Business Combination, Contingent Consideration, Liability							$ 5,000,000
Business Combination, Acquisition Related Costs		116,000		$ 335,000
Amortization of Intangible Assets				2,000,000
Payments to Acquire Businesses, Gross				2,000,000
Acquisition of Celleration, Inc [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life	10 years
Business Combination, Acquisition Related Costs		15,000		2,875,000
Business Combination Contingent Consideration Adjustments to Fair Value		469,000		623,000
Business Acquisition Initial Cash Payment	$ 15,500,000
Business Combination, Contingent Consideration, at Fair Value	15,570,000
Business Combination, Consideration Transferred	46,253,691
Business Combination Acquisition of transaction costs		2,739,000		3,589,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets		32,000,000		32,000,000
Goodwill	16,698,638
Payments to Acquire Businesses, Gross	$ 15,476,191
Business Combination, Contingent Consideration, Liability, Current		5,751,688		5,751,688
Business Combination, Contingent Consideration, Liability, Noncurrent		$ 10,441,457		10,441,457
Acquisition of Celleration, Inc [Member] | Common Stock [Member]
Business Acquisition [Line Items]
Consideration Paid By Issuing Shares Value				$ 500,000
Stock Issued During Period, Shares, Acquisitions	3,168,229
Acquisition of Celleration, Inc [Member] | UK [Member]
Business Acquisition [Line Items]
Percentage Of Incremental Net Sales				20.00%

Inventory (Details)

Inventory (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Inventory [Line Items]
Raw materials	$ 265,737	$ 197,514
Work in process	659,256	489,431
Finished goods	2,566,682	725,897
Less: Inventory reserve	(12,720)	(1,094)
Total	$ 3,478,955	$ 1,411,748

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Gross Amount	$ 38,843,333	$ 6,891,333
Accumulated Amortization	(4,060,277)	(2,504,040)
Net Carrying Amount	$ 34,783,056	$ 4,387,293
Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	10 years	10 years
Gross Amount	$ 32,539,000	$ 5,396,000
Accumulated Amortization	(3,244,200)	(1,934,733)
Net Carrying Amount	29,294,800	3,461,267
Customer relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amount	1,984,000	776,000
Accumulated Amortization	(401,304)	(308,871)
Net Carrying Amount	$ 1,582,696	$ 467,129
Customer relationships [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	9 years	9 years
Customer relationships [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	12 years	12 years
Distribution rights [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	5 years 3 months 7 days	5 years 3 months 7 days
Gross Amount	$ 400,000	$ 400,000
Accumulated Amortization	(154,023)	(96,880)
Net Carrying Amount	$ 245,977	$ 303,120
Tradename [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	3 years	3 years
Gross Amount	$ 111,000	$ 111,000
Accumulated Amortization	(52,417)	(24,667)
Net Carrying Amount	58,583	$ 86,333
Tradename One [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amount	3,601,000
Accumulated Amortization	0
Net Carrying Amount	$ 3,601,000
Non-compete [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	1 year	1 year
Gross Amount	$ 208,333	$ 208,333
Accumulated Amortization	(208,333)	(138,889)
Net Carrying Amount	$ 0	$ 69,444

Intangible Assets (Details Text

Intangible Assets (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 889,362	$ 232,670	$ 1,556,237	$ 529,847
Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year	2,445,598		2,445,598
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	3,557,446		3,557,446
Finite-Lived Intangible Assets, Amortization Expense, Year Two	3,532,779		3,532,779
Finite-Lived Intangible Assets, Amortization Expense, Year Three	3,518,804		3,518,804
Finite-Lived Intangible Assets, Amortization Expense, Year Four	$ 3,169,256		$ 3,169,256

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Accrued Liabilities Current Line Items [Line Items]
Salaries, benefits and incentive compensation	$ 1,877,363	$ 1,528,229
Professional fees	545,465	228,426
Royalty fees	423,786	100,537
Deferred revenue	94,851	78,523
Deferred lease incentive liability	8,337	8,337
Other	171,370	123,807
Total accrued expenses and other current liabilities	$ 3,121,172	$ 2,067,859

Debt (Details)

Debt (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Long-term debt	$ 15,500,000
Unamortized debt issuance and discount costs	(3,612,717)
Long-term debt, net	$ 11,887,283	$ 0

Debt (Details Textual)

Debt (Details Textual) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
	May. 29, 2015	Sep. 30, 2015	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Common Stock, Par or Stated Value Per Share		$ 0.001	$ 0.001		$ 0.001
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 5.5138	$ 5.5138
Derivative Liability		$ 1,567,364	$ 1,567,364	$ 280,157	$ 304,223	$ 933,465
Amortization of Debt Discount (Premium)			$ 326,118	$ 0
Warrant Expiration Period			five-year warrant
Common Stock Purchased By Warrants Issued			750,000
Fair Value, Inputs, Level 3 [Member]
Debt Instrument [Line Items]
Derivative Liability		1,567,364	$ 1,567,364		$ 304,223
Common Stock [Member]
Debt Instrument [Line Items]
Common Stock Purchased By Warrants Issued			750,000
Warrant [Member] | Fair Value, Inputs, Level 3 [Member]
Debt Instrument [Line Items]
Derivative Liability		2,682,710	$ 2,682,710
Interest Expense [Member]
Debt Instrument [Line Items]
Amortization of Financing Costs		72,258	98,427
Amortization of Debt Discount (Premium)		$ 168,932	227,691
Senior Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 15,500,000
Debt Issuance Cost			$ 1,256,125
Debt Instrument, Interest Rate Terms			accrues interest at an annual rate equal to the greater of (a) one-month LIBOR or 1% plus (b) 9.75%
Debt Instrument, Term			4 years
Debt Instrument, Payment Terms			is interest only for the first 24 months, followed by monthly amortization payments of $225,000, with the remaining unpaid balance due on the maturity date
Debt Instrument, Maturity Date, Description			The Company is required to pay an exit fee when the term loan is paid in full equal to the greater of 1% of the outstanding principal balance immediately prior to the final payment and $100,000.
Debt Instrument, Periodic Payment, Total	$ 225,000
Debt Instrument Prepayment Terms			The Credit Agreement requires the Company to prepay the outstanding principal amount of the term loan with 100% of the net cash proceeds received from specified asset sales, issuances or sales of equity and incurrences of borrowed money indebtedness, subject to certain exceptions.

Commitments and Contingencies43

Commitments and Contingencies (Details)	Sep. 30, 2015EUR (€)
Commitments And Contingencies [Line Items]
2,016	€ 2,500,000
2,017	€ 4,000,000

Commitments and Contingencies44

Commitments and Contingencies (Details Textual) - USD ($)	Jul. 15, 2011	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Commitments And Contingencies [Line Items]
Accrued Liabilities, Current		$ 3,121,172		$ 3,121,172		$ 2,067,859
Accounts Payable, Current		2,843,448		2,843,448		$ 1,757,742
AIQA Cedar Inc [Member]
Commitments And Contingencies [Line Items]
Accrued Liabilities, Current		372,275		372,275
Accounts Payable, Current		810		810
Alliqua Biomedical Subsidiary [Member]
Commitments And Contingencies [Line Items]
Contractual Obligation, Future Minimum Payments Due, Remainder of Fiscal Year		500,000		500,000
Contractual Obligation, Due in Next Twelve Months		600,000		600,000
Royalty Expense		125,000	$ 100,000	375,000	$ 300,000
Noble Fiber Technologies License Agreement [Member]
Commitments And Contingencies [Line Items]
Royalty Fee Percentage	9.75%
Sorbion Distributor Agreement [Member]
Commitments And Contingencies [Line Items]
Recorded Unconditional Purchase Obligation, Due in Next Rolling Twelve Months		$ 1,100,000		$ 1,100,000
Other Commitments, Description				the minimum annual purchase amounts noted below will be converted from Euros to U.S. Dollars with the exchange rate in effect on the last day of the preceding calendar year, provided that the exchange rate is not more than five percent greater or less than the exchange rate from Euros to U.S. Dollars of 1.10. If the exchange rate is five percent greater or less than 1.10, the rate will be rounded as necessary so that it is no more than five percent grater or five percent less.

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	$ 2,166,108	$ 1,779,134	$ 6,307,252	$ 8,875,080
Share Based Compensation Plan [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	2,257,367	1,842,465	6,580,379	9,018,264
Share Based Compensation Plan [Member] | Options [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	1,564,191	1,450,527	4,543,275	6,361,366
Share Based Compensation Plan [Member] | Warrants [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	0	13,496	0	208,530
Share Based Compensation Plan [Member] | Restricted stock units [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	0	0	0	180,715
Share Based Compensation Plan [Member] | Restricted stock [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	$ 693,176	$ 378,442	$ 2,037,104	$ 2,267,653

Stockholders' Equity (Details 1

Stockholders' Equity (Details 1)	9 Months Ended
	Sep. 30, 2015USD ($)shares
Officers [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance Date	Feb. 6, 2015
Shares Issued	600,000
Vesting Term	0 years	[1]
Grant Date Value | $	$ 3,738,000
Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance Date	Jun. 15, 2015
Shares Issued	120,000
Vesting Term	0 years	[2]
Grant Date Value | $	$ 630,000
Restricted Stock Total [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Issued	720,000
Grant Date Value | $	$ 4,368,000
[1]	Vests in three equal annual installments, with one-third vesting on each of February 6, 2016, February 6, 2017 and February 6, 2018.
[2]	Vests in four equal installments, with one-fourth vesting on the date of grant and one-fourth vesting on each of June 15, 2016, June 15, 2017 and June 15, 2018.

Stockholders' Equity (Details 2

Stockholders' Equity (Details 2) - Restricted Stock [Member]	9 Months Ended
	Sep. 30, 2015USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Non-vested, December 31, 2014 (in shares)	188,149
Number of Shares, Granted (in shares)	720,000
Number of Shares, Vested (in shares)	(170,247)
Number of Shares, Forfeited (in shares)	0
Number of Shares, Non-vested, September 30, 2015 (in shares)	737,902
Weighted Average Grant Date Fair Value, Non-vested, December 31, 2014 (in dollars per share) | $ / shares	$ 7.03
Weighted Average Grant Date Fair Value, Granted (in dollars per share) | $ / shares	6.07
Weighted Average Grant Date Fair Value, Vested (in dollars per share) | $ / shares	6.7
Weighted Average Grant Date Fair Value, Forfeited (in dollars per share) | $ / shares	0
Weighted Average Grant Date Fair Value, Non-vested, September 30, 2015 (in dollars per share) | $ / shares	$ 6.16
Total Grant Date Fair Value, Non-vested, December 31, 2014 | $	$ 1,322,096
Total Grant Date Fair Value, Granted | $	4,368,000
Total Grant Date Fair Value, Vested | $	(1,141,294)
Total Grant Date Fair Value, Forfeited | $	0
Total Grant Date Fair Value, Non-vested, September 30, 2015 | $	$ 4,548,802

Stockholders' Equity (Details 3

Stockholders' Equity (Details 3) - Warrant [Member]	9 Months Ended
	Sep. 30, 2015USD ($)$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award Line Items
Number of Options, Outstanding at Beginning of the period (in shares)	2,675,121
Number of Warrants, Issued (in shares)	750,000
Number of Warrants, Exercised (in shares)	(15,999)
Number of Warrants, Cancelled (in shares)	(36,572)
Number of Options, Outstanding at End of the period (in shares)	3,372,550
Number of Warrants, Exercisable, September 30, 2015 (in shares)	3,372,550
Weighted Average Exercise Price, Outstanding, Beginning of the period, (in dollars per share) | $ / shares	$ 5.76
Weighted Average Exercise Price, Issued (in dollars per share) | $ / shares	5.51
Weighted Average Exercise Price, Exercised (in dollars per share) | $ / shares	2.19
Weighted Average Exercise Price, Cancelled (in dollars per share) | $ / shares	7.88
Weighted Average Exercise Price, Outstanding, End of the period, (in dollars per share) | $ / shares	5.7
Weighted Average Exercise Price, Exercisable September 30, 2015 (in dollars per share) | $ / shares	$ 5.7
Weighted Average Remaining Life In Years, Outstanding, September 30, 2015 (Years)	3 years 3 months 18 days
Weighted Average Remaining Life In Years, Exercisable, September 30, 2015 (Years)	3 years 3 months 18 days
Intrinsic Value, Outstanding, September 30, 2015 | $	$ 101,864
Intrinsic Value, Exercisable, September 30, 2015 | $	$ 101,864

Stockholders' Equity (Details 4

Stockholders' Equity (Details 4) - Warrant [Member]	9 Months Ended
	Sep. 30, 2015$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	3,372,550
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 3 months 18 days
Warrants Exercisable, Number of Warrants	3,372,550
Exercise Price Range, 2.19 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 2.19
Warrants Outstanding, Number of Warrants	92,573
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years
Warrants Exercisable, Number of Warrants	92,573
Exercise Price Range, 3.02 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 3.02
Warrants Outstanding, Number of Warrants	74,286
Warrants Exercisable, Weighted Average Remaining Life In Years	1 year 4 months 24 days
Warrants Exercisable, Number of Warrants	74,286
Exercise Price Range, 3.50 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 3.50
Warrants Outstanding, Number of Warrants	2,286
Warrants Exercisable, Weighted Average Remaining Life In Years	1 year 7 months 6 days
Warrants Exercisable, Number of Warrants	2,286
Exercise Price Range, 4.24 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 4.24
Warrants Outstanding, Number of Warrants	780,191
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 8 months 12 days
Warrants Exercisable, Number of Warrants	780,191
Exercise Price Range, 4.38 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 4.38
Warrants Outstanding, Number of Warrants	188,444
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 1 month 6 days
Warrants Exercisable, Number of Warrants	188,444
Exercise Price Range, 4.81 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 4.81
Warrants Outstanding, Number of Warrants	8,889
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 1 month 6 days
Warrants Exercisable, Number of Warrants	8,889
Exercise Price Range, 5.51 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 5.51
Warrants Outstanding, Number of Warrants	750,000
Warrants Exercisable, Weighted Average Remaining Life In Years	4 years 8 months 12 days
Warrants Exercisable, Number of Warrants	750,000
Exercise Price Range, 5.69 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 5.69
Warrants Outstanding, Number of Warrants	1,040,880
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 1 month 6 days
Warrants Exercisable, Number of Warrants	1,040,880
Exercise Price Range, 8.75 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 8.75
Warrants Outstanding, Number of Warrants	7,143
Warrants Exercisable, Weighted Average Remaining Life In Years	4 months 24 days
Warrants Exercisable, Number of Warrants	7,143
Exercise Price Range, 10.50 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 10.50
Warrants Outstanding, Number of Warrants	427,858
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 6 months
Warrants Exercisable, Number of Warrants	427,858

Stockholders' Equity (Details 5

Stockholders' Equity (Details 5) - Employee Stock Option [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.78%	1.96%	1.72%	1.92%
Expected term (years)	6 years	5 years 11 months 23 days	5 years 11 months 16 days	5 years 11 months 8 days
Expected volatility	93.70%	100.56%	97.37%	102.36%
Expected dividends	0.00%	0.00%	0.00%	0.00%

Stockholders' Equity (Details 6

Stockholders' Equity (Details 6) - Employee Stock Option [Member] $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Outstanding at Beginning of the period (in shares)	4,817,660
Number of Options, Granted (in shares)	1,806,000
Number of Options, Exercised (in shares)	(75,919)
Number of Options, Forfeited (in shares)	(247,382)
Number of Options, Outstanding at End of the period (in shares)	6,300,359
Number of Options, Exercisable, September 30, 2015 (in shares)	3,077,608
Weighted Average Exercise Price, Outstanding, Beginning of the period, (in dollars per share) | $ / shares	$ 6.56
Weighted Average Exercise Price, Granted (in dollars per share) | $ / shares	5.5
Weighted Average Exercise Price, Exercised (in dollars per share) | $ / shares	4.38
Weighted Average Exercise Price, Forfeited (in dollars per share) | $ / shares	6.27
Weighted Average Exercise Price, Outstanding, End of the period, (in dollars per share) | $ / shares	6.29
Weighted Average Exercise Price, Exercisable September 30, 2015 (in dollars per share) | $ / shares	$ 6.06
Weighted Average Remaining Life In Years, Outstanding, September 30, 2015 (Years)	7 years 7 months 6 days
Weighted Average Remaining Life In Years, Exercisable, Exercisable, September 30, 2015 (Years)	6 years 4 months 24 days
Intrinsic Value, Outstanding, September 30, 2015 | $	$ 0
Intrinsic Value, Exercisable, September 30, 2015 | $	$ 0

Stockholders' Equity (Details 7

Stockholders' Equity (Details 7) - Employee Stock Option [Member]	9 Months Ended
	Sep. 30, 2015$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Outstanding Number of Options (in shares) | shares	6,300,359
Options Exercisable, Weighted Average Remaining Life in Years (in years)	6 years 4 months 24 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	3,077,608
Exercise Price Range 3.28 - 3.99 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 3.28
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	3.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 3.37
Options Outstanding, Outstanding Number of Options (in shares) | shares	413,971
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 3.36
Options Exercisable, Weighted Average Remaining Life in Years (in years)	7 years 7 months 6 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	403,971
Exercise Price Range 4.00 - 4.99 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 4
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	4.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 4.58
Options Outstanding, Outstanding Number of Options (in shares) | shares	1,553,982
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 4.39
Options Exercisable, Weighted Average Remaining Life in Years (in years)	3 years 8 months 12 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	833,342
Exercise Price Range 5.00 - 5.99 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 5
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	5.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 5.26
Options Outstanding, Outstanding Number of Options (in shares) | shares	723,427
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 5.45
Options Exercisable, Weighted Average Remaining Life in Years (in years)	6 years 1 month 6 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	220,523
Exercise Price Range 6.00 - 6.99 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 6
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	6.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 6.59
Options Outstanding, Outstanding Number of Options (in shares) | shares	2,258,629
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 6.77
Options Exercisable, Weighted Average Remaining Life in Years (in years)	7 years 9 months 18 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	958,137
Exercise Price Range 7.00 - 7.99 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 7
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	7.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 7.75
Options Outstanding, Outstanding Number of Options (in shares) | shares	31,000
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 7.75
Options Exercisable, Weighted Average Remaining Life in Years (in years)	8 years 7 months 6 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	10,333
Exercise Price Range 8.00 - 8.99 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 8
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	8.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 8.74
Options Outstanding, Outstanding Number of Options (in shares) | shares	790,898
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 8.74
Options Exercisable, Weighted Average Remaining Life in Years (in years)	6 years 10 months 24 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	481,245
Exercise Price Range 9.00 - 9.99 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 9
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	9.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 9
Options Outstanding, Outstanding Number of Options (in shares) | shares	264,833
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 9
Options Exercisable, Weighted Average Remaining Life in Years (in years)	7 years 1 month 6 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	113,828
Exercise Price Range 10.00 - 26.69 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 10
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	26.69
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 10.96
Options Outstanding, Outstanding Number of Options (in shares) | shares	263,619
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 11.01
Options Exercisable, Weighted Average Remaining Life in Years (in years)	7 years 6 months
Options Exercisable, Exercisable Number of Options (in shares) | shares	56,229

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($)	Jan. 06, 2014	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense		$ 2,166,108	$ 1,779,134	$ 6,307,252	$ 8,875,080
Proceeds from Issuance of Common Stock				32,196,540	14,372,503
Proceeds from Warrant Exercises				0	$ 5,225,587
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total		$ 7,202,954		$ 7,202,954
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition				1 year 7 months 6 days
Stock Issued During Period Shares Warrants Exercised				75,919
Number Of Warrants To Purchase Common Stock Exercised				75,919
Warrants Exercised, Intrinsic Value				$ 85,798
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				1,806,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value				$ 7,711,629
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 3.78	$ 4.29	$ 4.27	$ 6.21
Employee Stock Option [Member] | Cashless Excisable [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from Warrant Exercises				$ 332,271
Employee Stock Option One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value				1,719,000
Employee Stock Option Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value				87,000
Employee Stock Option Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value				4,500
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense		$ 91,259	$ 63,331	273,127	$ 143,184
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense		$ 2,166,108	$ 1,779,134	$ 6,307,252	8,875,080
Plan 2011 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		1,828,571		1,828,571
Allocated Share-based Compensation Expense					$ 98,915
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	194,667			117,336
Plan 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		5,500,000		5,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				2,931,488
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized				3,500,000
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Forfeiture Rate				0.00%
Minimum [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price				$ 4.06
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Forfeiture Rate				5.00%
Maximum [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price				$ 6.23
Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares				90,000
Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares				1,711,500
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, New Issues				7,582,418
Sale of Stock, Price Per Share		$ 4.55		$ 4.55
4.38 Exercise Price [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Investment Warrants, Exercise Price				$ 4.38
Non Employee Director [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total		$ 5,132		$ 5,132
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total		$ 2,654,114		$ 2,654,114
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares				170,247
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition				1 year 7 months 6 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				720,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value				$ 6.07
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants To Purchase Common Stock				15,999
Number Of Warrants To Purchase Common Stock Exercised				8,970
Warrants Exercised, Intrinsic Value				$ 44,906
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				750,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price				$ 5.51
Investment Warrants, Exercise Price				$ 2.19
Warrant Liabilities [Member] | Fair Value, Inputs, Level 3 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants To Purchase Common Stock				816,287
Exercise Price Of Warrants		$ 5.24		$ 5.24

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	May. 29, 2015
Income Taxes [Line Items]
Income Tax Expense (Benefit)	$ 128,795	$ 3,500	$ (1,308,105)	$ 10,500
Acquisition of Celleration, Inc [Member]
Income Taxes [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Current	$ 1,400,000		$ 1,400,000		$ 2,754,770

Related Party (Details Textual)

Related Party (Details Textual) - USD ($)	Jan. 06, 2014	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Related Party Transaction [Line Items]
Allocated Share-based Compensation Expense		$ 2,166,108	$ 1,779,134	$ 6,307,252	$ 8,875,080
Plan 2011 [Member]
Related Party Transaction [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	194,667			117,336
Allocated Share-based Compensation Expense					$ 98,915
Option Cancellation and Release Agreement [Member]
Related Party Transaction [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	278,096
Option Cancellation and Release Agreement [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price	$ 6.34
Option Cancellation and Release Agreement [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price	$ 9.19

Concentration of Risk (Details)

Concentration of Risk (Details) - Customer A [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	6.00%	22.00%	11.00%	31.00%
Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	5.00%

Fair Value Measurement (Details

Fair Value Measurement (Details) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 304,223	$ 933,465
Initial fair value of contingent consideration	15,570,000	2,700,000
Change in fair value of warrant liability	(1,388,071)	19,324
Value of warrants issued	2,682,710	0
Value of warrants exercised	(31,498)	(672,632)
Ending balance	1,567,364	280,157
Contingent Consideration [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	2,931,598	0
Initial fair value of contingent consideration	15,570,000	2,700,000
Change in fair value of warrant liability	957,732	194,034
Ending balance	$ 19,459,330	$ 2,894,034

Fair Value Measurement (Detai58

Fair Value Measurement (Details 1) - USD ($)	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013
Liabilities:
Warrant liabilities	$ 1,567,364	$ 304,223	$ 280,157	$ 933,465
Fair Value, Inputs, Level 1 [Member]
Liabilities:
Warrant liabilities	0	0
Contingent consideration	0	0
Total liabilities	0	0
Fair Value, Inputs, Level 2 [Member]
Liabilities:
Warrant liabilities	0	0
Contingent consideration	0	0
Total liabilities	0	0
Fair Value, Inputs, Level 3 [Member]
Liabilities:
Warrant liabilities	1,567,364	304,223
Contingent consideration	19,459,330	2,931,598
Total liabilities	$ 21,026,694	$ 3,235,821

Fair Value Measurement (Detai59

Fair Value Measurement (Details Textual) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Liabilities Measured on Recurring Basis, Change in Unrealized Gain (Loss)	$ 1,466,208	$ 1,384,157
Derivative Liability	$ 1,567,364	$ 1,567,364	$ 280,157	$ 304,223	$ 933,465
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 5.5138	$ 5.5138
Common Stock Purchased By Warrants Issued		750,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements		$ 31,498	$ 672,632
Common Stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants To Purchase Common Stock		9,142
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability	$ 1,567,364	$ 1,567,364		$ 304,223
Fair Value, Inputs, Level 3 [Member] | Common Stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Expected Volatility Rate		98.25%
Fair Value Assumptions, Risk Free Interest Rate		0.96%
Fair Value Assumptions, Expected Term		2 years 6 months 7 days
Fair Value Assumptions, Expected Dividend Rate		0.00%
Fair Value, Liabilities Measured on Recurring Basis, Change in Unrealized Gain (Loss)	0	$ 3,914
Fair Value, Inputs, Level 3 [Member] | Credit Agreement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Expected Volatility Rate		98.25%
Fair Value Assumptions, Risk Free Interest Rate		1.49%
Fair Value Assumptions, Expected Term		5 years
Fair Value Assumptions, Expected Dividend Rate		0.00%
Derivative Liability	2,682,710	$ 2,682,710
Fair Value, Inputs, Level 3 [Member] | Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Expected Volatility Rate		93.70%
Fair Value Assumptions, Expected Dividend Rate		0.00%
Warrants To Purchase Common Stock		816,287
Derivative Liability	$ 1,567,364	$ 1,567,364
Fair Value, Inputs, Level 3 [Member] | Maximum [Member] | Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Risk Free Interest Rate		1.37%
Fair Value Assumptions, Expected Term		4 years 8 months 1 day
Fair Value, Inputs, Level 3 [Member] | Minimum [Member] | Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Risk Free Interest Rate		0.64%
Fair Value Assumptions, Expected Term		2 years 1 month 10 days